Please login to the form below

Not currently logged in
Email:
Password:

Jardiance

This page shows the latest Jardiance news and features for those working in and with pharma, biotech and healthcare.

Trial of Amgen, Servier’s heart failure drug clears interim check

Trial of Amgen, Servier’s heart failure drug clears interim check

Other drugs in the SGLT2 class – including Boehringer Ingelheim and Eli Lilly’s Jardiance (empagliflozin) – are also being tested in heart failure indications.

Latest news

More from news
Approximately 23 fully matching, plus 61 partially matching documents found.

Latest Intelligence

  • Market dynamics, marketing and analytics Market dynamics, marketing and analytics

    The remaining two SGLT2s are growing faster than the market, with Jardiance (empagliflozin) leading the market in terms of growth. ... In contrast Jardiance and Vipidia are still growing where Jardiance (the 3rd entrant SGLT2) appears to have overtaken

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics